A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
Venous Thrombosis and Pulmonary Embolism
DRUG: Rivaroxaban (Xarelto, BAY 59-7939)
Treatment satisfaction burden score (ACTS), Patient reported treatment satisfaction will be assessed with regard to the Anti-Clot Treatment Scale (ACTS) burden score for the use of rivaroxaban for treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in patients with active cancer changing to this therapy., At 4 weeks
Preferences regarding the attributes of the anticoagulation medication options LMWH, VKA, rivaroxaban using DCE survey, Discrete Choice Experiment (DCE) based preference of patients for rivaroxaban versus other anticoagulants in a semi-structured telephone interview

LMWH: Low Molecular Weight Heparin; VKA: Vitamin K Antagonist, Between 4 weeks and 3 months|Change of ACTS score over time, To assess patient reported outcomes by means of the Anti-Clot Treatment Scale (ACTS) questionnaire, At 3 months and 6 months|Patient's quality of life using the FACIT-Fatigue questionnaire, To assess patient reported outcomes on quality of life using the FACIT-Fatigue questionnaire (Functional Assessment of Chronic Illness Therapy), Up to 6 months|Type of index VTE (venous thromboembolism) event, At baseline|Date of index VTE event, At baseline|Type (trade name) of initial anticoagulation treatment, At baseline|Duration of initial anticoagulation treatment, At baseline|Reason for drug switch to rivaroxaban, Menu items: patient choice, physician choice, side effects, other, At baseline|Planned duration of anticoagulation with rivaroxaban, At baseline|Actual duration of anticoagulation with rivaroxaban, Up to 6 months|Dosage of rivaroxaban, Up to 6 months|Reason for any potential dose adjustments during course of treatment with rivaroxaban, Menu items: side effects, intervention, other, Up to 6 months|Reasons for any switch from rivaroxaban treatment, Menu items: patient choice, physician choice, side effects, other, Up to 6 months|Reasons for permanent cessation of rivaroxaban treatment, Menu items: patient choice, physician choice, side effects, other, Up to 6 months|TNM Staging (Clinical characteristics of cancer disease), Assessment according to TNM (Tumor, Lymph Node and Metastases) classification. TNM is developed and maintained by the Union for International Cancer Control (UICC), At baseline|Primary site of cancer (Clinical characteristics of cancer disease), Following Medical Dictionary for Regulatory Activities (MedDRA) coding system, At baseline|Type of bleeding events, Up to 6 months|Number of bleeding events, Up to 6 months|Type of thromboembolic events, Up to 6 months|Number of thromboembolic events, Up to 6 months
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).